section name header

Pronunciation ⬇

eye-soe-proe-TER-e-nole

Classifications ⬆ ⬇

Therapeutic Classification: antiarrhythmics, bronchodilators

Pharmacologic Classification: adrenergics

Indications ⬆ ⬇

High Alert


Action ⬆ ⬇

  • Results in the accumulation of cyclic adenosine monophosphate (cAMP) at beta-adrenergic receptors.
  • Produces bronchodilation.
  • Produces positive inotropic and chronotropic effects.
Therapeutic effects:
  • Bronchodilation.
  • Increased heart rate.

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Metabolism occurs in the lung, liver, and other tissues; 50% excreted unchanged by the kidneys.

Half-Life: 2.5–5 min.

Time/Action Profile ⬆ ⬇

(bronchodilation)

ROUTEONSETPEAKDURATION
IVimmediateunknown<1 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: angina, hypertension, tachycardia, ARRHYTHMIAS

Endo: hyperglycemia

GI: nausea, vomiting, xerostomia

Neuro: nervousness, restlessness, tremor, headache, insomnia

Misc: pink/red discoloration of saliva

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Toxicity and Overdose:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Isuprel

Code ⬆

NDC Code